Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
Azitra 在皮肤病学研究学会年会上公布来自 ATR-04 的临床前数据
- ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US
- Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin
- Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin
- Increases human beta defensin 18-fold vs. vehicle on human skin model
- ATR-04 正在开发用于表皮生长因子受体抑制剂 (eGFRI) 诱发的皮肤毒性，该毒性影响了美国大约 150,000 名患者
- 减少对甲氧西林的耐药性 金黄色葡萄球菌 开启率提高了99％ 活体外 猪皮
- 与接受厄洛替尼治疗的皮肤相比，在人体皮肤模型中，IL-36g（一种促炎细胞因子，可在 EGFRI 诱发的毒性中引起炎症）降低 75%
- 与人体皮肤模型上的载具相比，人体 β 防御素提高了 18 倍